{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:08:53Z","timestamp":1784099333091,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle\u2010Aquitaine, a southwestern French region with around six million inhabitants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was performed from the Nouvelle\u2010Aquitaine regional databases of the French healthcare insurance system. It included all individuals who received at least one pregabalin reimbursement between 24 May 2020 and 24 May 2022. We analysed changes in the prevalence and incidence of pregabalin use and misuse, as well as the characteristics of pregabalin users. Misuse was defined as use exceeding 600\u2009mg\/day or engaging in doctor or pharmacy shopping. Two time periods were considered: 24 May 2020\u201323 May 2021 and 24 May 2021\u201324 May 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The implementation of secured prescriptions led to a 16.9% [16.5; 17.3] decrease in pregabalin prevalent use and in a 36.6% [36.1; 37.1] decrease in pregabalin incident use. Additionally, pregabalin misuse reduced by 7.7% [7.0; 8.4] for prevalent misuse and 71.5% [69.3; 73.6] for incident one. Most users were women aged over 60. Patients' characteristics changed between the two periods. Use of psychotropic and opioid treatment increased in prevalent users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The introduction of secured prescription forms was associated with a marked reduction in pregabalin use and misuse in Nouvelle\u2010Aquitaine, especially in incident misuse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70500","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T03:59:20Z","timestamp":1771819160000},"page":"2212-2219","source":"Crossref","is-referenced-by-count":0,"title":["Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle\u2010Aquitaine"],"prefix":"10.1002","volume":"92","author":[{"given":"Maika","family":"Munech\u2010Herran","sequence":"first","affiliation":[{"name":"Department of General Practice University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Moysan","sequence":"additional","affiliation":[{"name":"Direction R\u00e9gionale du Service M\u00e9dical de Nouvelle Aquitaine  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lescarret","sequence":"additional","affiliation":[{"name":"Direction R\u00e9gionale du Service M\u00e9dical de Nouvelle Aquitaine  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-148X","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD  Bordeaux France"},{"name":"CHU de Bordeaux, Service de Pharmacologie m\u00e9dicale \u2013 UG Pharmaco\u00e9pid\u00e9miologie et bon usage du m\u00e9dicament  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-5483","authenticated-orcid":false,"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD  Bordeaux France"},{"name":"CHU de Bordeaux, Service de Pharmacologie m\u00e9dicale \u2013 UG Pharmaco\u00e9pid\u00e9miologie et bon usage du m\u00e9dicament  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-9629","authenticated-orcid":false,"given":"Nicolas","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Department of General Practice University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.09.019"},{"issue":"144","key":"e_1_2_12_3_1","first-page":"43633","article-title":"Schedules of controlled substances: placement of pregabalin into schedule V. Final rule","volume":"70","author":"Drug Enforcement Administration, Department of Justice","year":"2005","journal-title":"Federal Register"},{"key":"e_1_2_12_4_1","unstructured":"European Medicines Agency.EPAR summary for the public: Lyrica \u2013 pregabalin. London: EMA;2010."},{"key":"e_1_2_12_5_1","unstructured":"French Health Authority.Transparency commission: Opinion on pregabalin. Paris: HAS;2017."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.676224"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12358"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1892719"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16261"},{"key":"e_1_2_12_10_1","unstructured":"Drug dependency assessment and information center of Toulouse.Pregabalin expert report. Toulouse: CEIP\u2010A;2020."},{"key":"e_1_2_12_11_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.Annual report 2010: state of the drugs phenomenon in Europe. Lisbon: EMCDDA;2010."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13892"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2020.02.008"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100700\u2010x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010024\u201001095\u2010y"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010024\u201001064\u20105"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010020\u201000985\u20106"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010013\u20101594\u20105"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001432\u20107"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100579"},{"key":"e_1_2_12_22_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Pregabalin (Lyrica) gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April [Internet]. London: UK government;2019. Available from:https:\/\/www.gov.uk\/drug-safety-update\/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april"},{"key":"e_1_2_12_23_1","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9.Pr\u00e9gabaline (Lyrica et g\u00e9n\u00e9riques): modification des conditions de prescription et d\u00e9livrance pour limiter le m\u00e9susage [Internet]. Saint\u2010Denis: ANSM.2021. Available from:https:\/\/ansm.sante.fr\/actualites\/pregabaline-lyrica-et-generiques-modification-des-conditions-de-prescription-et-delivrance-pour-limiter-le-mesusage"},{"key":"e_1_2_12_24_1","unstructured":"French Public Health Code. Order of March 31 1999 setting technical specifications for prescriptions mentioned in article R. 5132\u20135 (version in effect on October 22 2024)."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.56746\/EXERCER.2020.163.204"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2556"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_12_28_1","unstructured":"Documentation du SNDS & SNDS OMOP. Les bases du SNDS de l'alimentation \u00e0 la restitution des donn\u00e9es [Internet].2022. [cited 2025 April 10]. Available from:https:\/\/documentation-snds.health-data-hub.fr\/snds\/introduction\/02-bases-snds.html#les-datamarts-bo-des-bases-thematiques-avec-des-donnees-agregees"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010019\u201002737\u20107"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228495"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100042\u2010101868"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010013\u20101557\u2010x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102018\u2010027443"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3673"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.01.475"},{"issue":"2","key":"e_1_2_12_36_1","first-page":"S1","article-title":"The concise guide to PHARMACOLOGY 2023\/24: introduction and other protein targets","volume":"180","author":"Alexander SPH","year":"2023","journal-title":"British Journal of Pharmacology"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101851"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010017\u20102503\u2010x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.10.037"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101120"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12368"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S232409"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2024.10.058"},{"key":"e_1_2_12_44_1","unstructured":"L'Assurance maladie.Open Medic: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments \u2010 2014 \u00e0 2024. [Internet]. Paris: L'Assurance maladie [cited 2025 April 10]. Available from:https:\/\/www.assurance-maladie.ameli.fr\/etudes-et-donnees\/open-medic-base-complete-depenses-medicaments"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:34:04Z","timestamp":1784097244000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/bcp.70500"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70500","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}